ADC Therapeutics SA (ADCT)
ADC Therapeutics SA Statistics
Share Statistics
ADC Therapeutics SA has 99.18M shares outstanding. The number of shares has increased by 2.97% in one year.
| Shares Outstanding | 99.18M |
| Shares Change (YoY) | 2.97% |
| Shares Change (QoQ) | 2.48% |
| Owned by Institutions (%) | 53.89% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,511 |
| FTD / Avg. Volume | 0.41% |
Short Selling Information
The latest short interest is 4.53M, so 4.57% of the outstanding shares have been sold short.
| Short Interest | 4.53M |
| Short % of Shares Out | 4.57% |
| Short % of Float | 5.81% |
| Short Ratio (days to cover) | 11.75 |
Valuation Ratios
The PE ratio is -1.22 and the forward PE ratio is -1.05. ADC Therapeutics SA's PEG ratio is 0.03.
| PE Ratio | -1.22 |
| Forward PE | -1.05 |
| PS Ratio | 2.79 |
| Forward PS | 0.4 |
| PB Ratio | -0.95 |
| P/FCF Ratio | -1.55 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for ADC Therapeutics SA.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.82, with a Debt / Equity ratio of -1.62.
| Current Ratio | 3.82 |
| Quick Ratio | 3.59 |
| Debt / Equity | -1.62 |
| Debt / EBITDA | -3.2 |
| Debt / FCF | -2.63 |
| Interest Coverage | -2.6 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $263,422.05 |
| Profits Per Employee | $-600,174.9 |
| Employee Count | 263 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 0.32 |
Taxes
| Income Tax | 166K |
| Effective Tax Rate | -0.11% |
Stock Price Statistics
The stock price has increased by -69.56% in the last 52 weeks. The beta is 1.56, so ADC Therapeutics SA's price volatility has been higher than the market average.
| Beta | 1.56 |
| 52-Week Price Change | -69.56% |
| 50-Day Moving Average | 1.5 |
| 200-Day Moving Average | 2.32 |
| Relative Strength Index (RSI) | 54.56 |
| Average Volume (20 Days) | 367,603 |
Income Statement
In the last 12 months, ADC Therapeutics SA had revenue of 69.28M and earned -157.85M in profits. Earnings per share was -1.62.
| Revenue | 69.28M |
| Gross Profit | 63.33M |
| Operating Income | -130.65M |
| Net Income | -157.85M |
| EBITDA | -102.65M |
| EBIT | -105.92M |
| Earnings Per Share (EPS) | -1.62 |
Balance Sheet
The company has 250.87M in cash and 328.09M in debt, giving a net cash position of -77.22M.
| Cash & Cash Equivalents | 250.87M |
| Total Debt | 328.09M |
| Net Cash | -77.22M |
| Retained Earnings | -1.49B |
| Total Assets | 321.98M |
| Working Capital | 226.92M |
Cash Flow
In the last 12 months, operating cash flow was -123.83M and capital expenditures -867K, giving a free cash flow of -124.7M.
| Operating Cash Flow | -123.83M |
| Capital Expenditures | -867K |
| Free Cash Flow | -124.7M |
| FCF Per Share | -1.28 |
Margins
Gross margin is 91.41%, with operating and profit margins of -188.59% and -227.84%.
| Gross Margin | 91.41% |
| Operating Margin | -188.59% |
| Pretax Margin | -225.37% |
| Profit Margin | -227.84% |
| EBITDA Margin | -148.17% |
| EBIT Margin | -188.59% |
| FCF Margin | -180% |
Dividends & Yields
ADCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ADCT is $8, which is 455.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 455.6% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -6.35 |
| Piotroski F-Score | 2 |